<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2bbc8fb5-37a0-49a2-88e4-922c4b8dea28,g:76b63af8-607f-4b3f-a750-f8a8dfc06213-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2b8d9abe-3a4c-4b40-b19e-f9db5ff51ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_485b870c-2318-4476-b242-d169fb8f5938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2b8d9abe-3a4c-4b40-b19e-f9db5ff51ceb" xlink:to="loc_us-gaap_Liabilities_485b870c-2318-4476-b242-d169fb8f5938" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_88b26685-5214-4243-88f2-eec7e71421ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2b8d9abe-3a4c-4b40-b19e-f9db5ff51ceb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_88b26685-5214-4243-88f2-eec7e71421ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_06ae0cb8-bdb0-41a0-b819-013bcac2e4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2b8d9abe-3a4c-4b40-b19e-f9db5ff51ceb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_06ae0cb8-bdb0-41a0-b819-013bcac2e4fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c6803c6-9406-4b17-a6ed-0e7ef4e64804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a25f5ae6-e3ca-4d98-b1d1-6dcf880040cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6c6803c6-9406-4b17-a6ed-0e7ef4e64804" xlink:to="loc_us-gaap_CommonStockValue_a25f5ae6-e3ca-4d98-b1d1-6dcf880040cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_175d0f45-c23a-403a-9a57-673e05e0d5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6c6803c6-9406-4b17-a6ed-0e7ef4e64804" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_175d0f45-c23a-403a-9a57-673e05e0d5e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7b064640-eca8-4f78-a9e6-181215ff73c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7b064640-eca8-4f78-a9e6-181215ff73c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_050413b6-5677-42ad-ab81-9d1fbb5b297a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_050413b6-5677-42ad-ab81-9d1fbb5b297a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dc69530b-e236-4620-a378-572eede0aedb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_Goodwill_dc69530b-e236-4620-a378-572eede0aedb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_a9e98c66-a0b6-4b42-95c5-0d324f75dfdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_InventoryNoncurrent_a9e98c66-a0b6-4b42-95c5-0d324f75dfdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cb705738-19e9-4cf4-9e7d-8e48cae72f0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_AssetsCurrent_cb705738-19e9-4cf4-9e7d-8e48cae72f0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0280d698-61ce-43d8-92d9-6b2eff95a69e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0280d698-61ce-43d8-92d9-6b2eff95a69e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0b4ae891-12d9-48e7-bb20-9901d571f181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0b4ae891-12d9-48e7-bb20-9901d571f181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c1fb2807-2385-4d91-a59e-fb9f45479c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5fc39202-fd43-4525-a33e-04ad4a968f95" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c1fb2807-2385-4d91-a59e-fb9f45479c7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7d29502d-1399-4765-8ed8-ba5eb767ac85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b406b25c-66a2-4326-a384-59ba5a626837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d29502d-1399-4765-8ed8-ba5eb767ac85" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b406b25c-66a2-4326-a384-59ba5a626837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_bb75b1e6-4d15-4305-9a0c-081e4c06c81e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d29502d-1399-4765-8ed8-ba5eb767ac85" xlink:to="loc_us-gaap_AccountsPayableCurrent_bb75b1e6-4d15-4305-9a0c-081e4c06c81e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6b298f44-5af8-4367-9d1e-1a3cc64b98f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d29502d-1399-4765-8ed8-ba5eb767ac85" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6b298f44-5af8-4367-9d1e-1a3cc64b98f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_62681849-d93c-4af7-a5ae-a33035210aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d29502d-1399-4765-8ed8-ba5eb767ac85" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_62681849-d93c-4af7-a5ae-a33035210aab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_13cd71a2-5672-404c-8d4f-b9dccf4da83a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d29502d-1399-4765-8ed8-ba5eb767ac85" xlink:to="loc_us-gaap_LinesOfCreditCurrent_13cd71a2-5672-404c-8d4f-b9dccf4da83a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1fc9fb5e-0588-4e98-af01-fe4fd3834c67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_a28131a7-542c-4ae9-a2dc-ac19e52c4f30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1fc9fb5e-0588-4e98-af01-fe4fd3834c67" xlink:to="loc_us-gaap_LongTermLineOfCredit_a28131a7-542c-4ae9-a2dc-ac19e52c4f30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a719d0a9-6971-4b4e-a74e-5657c32e89de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1fc9fb5e-0588-4e98-af01-fe4fd3834c67" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a719d0a9-6971-4b4e-a74e-5657c32e89de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_782c5c91-73ab-4df1-8737-bf0fe85025a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1fc9fb5e-0588-4e98-af01-fe4fd3834c67" xlink:to="loc_us-gaap_LiabilitiesCurrent_782c5c91-73ab-4df1-8737-bf0fe85025a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_489ffd8f-71e0-4f89-9dff-43d6a8443482" xlink:href="cpix-20200930.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1fc9fb5e-0588-4e98-af01-fe4fd3834c67" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_489ffd8f-71e0-4f89-9dff-43d6a8443482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_03a9a98c-14f3-43e8-a5a6-ba88c1ba87e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff39336f-ad19-43c1-ae98-7bf8b07ce912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_03a9a98c-14f3-43e8-a5a6-ba88c1ba87e6" xlink:to="loc_us-gaap_StockholdersEquity_ff39336f-ad19-43c1-ae98-7bf8b07ce912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_f39760df-0799-4c74-bb2c-306fd2d2defa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_03a9a98c-14f3-43e8-a5a6-ba88c1ba87e6" xlink:to="loc_us-gaap_MinorityInterest_f39760df-0799-4c74-bb2c-306fd2d2defa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_03053b79-a214-47f1-b9c9-9c7c7d95bb92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e978d4d2-ef92-402d-838c-221904bbcc3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_03053b79-a214-47f1-b9c9-9c7c7d95bb92" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e978d4d2-ef92-402d-838c-221904bbcc3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_49129f5e-246a-4473-9934-8c976ff6deb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_03053b79-a214-47f1-b9c9-9c7c7d95bb92" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_49129f5e-246a-4473-9934-8c976ff6deb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ce7b05bd-f352-4345-aa4d-38f59fc849c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_03053b79-a214-47f1-b9c9-9c7c7d95bb92" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ce7b05bd-f352-4345-aa4d-38f59fc849c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_7cbebfe0-9418-4acd-9407-a58bfae148aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_03053b79-a214-47f1-b9c9-9c7c7d95bb92" xlink:to="loc_us-gaap_OtherAssetsCurrent_7cbebfe0-9418-4acd-9407-a58bfae148aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4d945b01-ff1b-4dd6-9a57-1352ccd16e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_03053b79-a214-47f1-b9c9-9c7c7d95bb92" xlink:to="loc_us-gaap_InventoryNet_4d945b01-ff1b-4dd6-9a57-1352ccd16e25" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b74a4710-ed73-40c5-8490-32640bf7a717" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d93c2f7c-cf8b-415e-a61c-d4d20046e3af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b74a4710-ed73-40c5-8490-32640bf7a717" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d93c2f7c-cf8b-415e-a61c-d4d20046e3af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_3161f181-911a-4dd9-8ee0-20fd12542c48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b74a4710-ed73-40c5-8490-32640bf7a717" xlink:to="loc_us-gaap_SellingAndMarketingExpense_3161f181-911a-4dd9-8ee0-20fd12542c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3247ebfa-a98f-4a03-8d1b-c1d6d83022b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b74a4710-ed73-40c5-8490-32640bf7a717" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3247ebfa-a98f-4a03-8d1b-c1d6d83022b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9ecde327-ddc7-4fc2-b212-8f2797c9273a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b74a4710-ed73-40c5-8490-32640bf7a717" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9ecde327-ddc7-4fc2-b212-8f2797c9273a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3b67ea13-2dda-4340-86c7-db9c4cf5ea59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_b74a4710-ed73-40c5-8490-32640bf7a717" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3b67ea13-2dda-4340-86c7-db9c4cf5ea59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c387623c-cfb2-4f58-9a32-c47b0a0e6e2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b0866bd5-5ca8-4cad-a7f5-35df7f44e1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c387623c-cfb2-4f58-9a32-c47b0a0e6e2b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b0866bd5-5ca8-4cad-a7f5-35df7f44e1ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_08284c47-b8a2-44ab-a56f-83efb3098a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c387623c-cfb2-4f58-9a32-c47b0a0e6e2b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_08284c47-b8a2-44ab-a56f-83efb3098a29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8b2d57ba-4b6e-4f2e-92a8-7420d1c0d206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5145480b-408b-4742-b9a0-5f41a2ca9d30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8b2d57ba-4b6e-4f2e-92a8-7420d1c0d206" xlink:to="loc_us-gaap_ProfitLoss_5145480b-408b-4742-b9a0-5f41a2ca9d30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a9c791ff-ff4c-4f1b-971a-a98771ab3394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8b2d57ba-4b6e-4f2e-92a8-7420d1c0d206" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a9c791ff-ff4c-4f1b-971a-a98771ab3394" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7c62d53a-ee01-41e0-bb28-80a55b585bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b69e3a6a-c3cf-40a2-baac-a219da4857e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7c62d53a-ee01-41e0-bb28-80a55b585bf8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b69e3a6a-c3cf-40a2-baac-a219da4857e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1e3e94fe-01a5-4642-bf28-a13c37b62a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7c62d53a-ee01-41e0-bb28-80a55b585bf8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1e3e94fe-01a5-4642-bf28-a13c37b62a57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f2ceb798-412f-416e-8cdf-9d37c06011cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d0b7617-5e45-44c8-ace1-2182fb546783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f2ceb798-412f-416e-8cdf-9d37c06011cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d0b7617-5e45-44c8-ace1-2182fb546783" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_632fb421-51eb-4214-b294-17b155872317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f2ceb798-412f-416e-8cdf-9d37c06011cf" xlink:to="loc_us-gaap_CostsAndExpenses_632fb421-51eb-4214-b294-17b155872317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_16795fc2-4894-43de-8813-d3749f424d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_deea9a26-2e48-4b2d-8c44-0f1f96d68384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_16795fc2-4894-43de-8813-d3749f424d8c" xlink:to="loc_us-gaap_OperatingIncomeLoss_deea9a26-2e48-4b2d-8c44-0f1f96d68384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_780507a4-cb3f-4515-a90a-a7d3c72ef984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_16795fc2-4894-43de-8813-d3749f424d8c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_780507a4-cb3f-4515-a90a-a7d3c72ef984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_64cdef20-91b8-445c-90eb-b2b5cfa3ecf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_16795fc2-4894-43de-8813-d3749f424d8c" xlink:to="loc_us-gaap_InterestExpense_64cdef20-91b8-445c-90eb-b2b5cfa3ecf9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2f94991-7861-4e8d-8144-5597dec19837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c12bb0c-8875-4240-980d-b18d280330a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2f94991-7861-4e8d-8144-5597dec19837" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c12bb0c-8875-4240-980d-b18d280330a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_508690cf-a6e8-4035-aa4b-a5c2cd7cff20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2f94991-7861-4e8d-8144-5597dec19837" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_508690cf-a6e8-4035-aa4b-a5c2cd7cff20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f0b29bba-9506-45b9-98a3-d669dae1c2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f2f94991-7861-4e8d-8144-5597dec19837" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f0b29bba-9506-45b9-98a3-d669dae1c2a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b783fd-7ed2-4f67-af6d-1656dcfba7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_184fd780-2fca-49a3-8e7e-0bc90dc34763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b783fd-7ed2-4f67-af6d-1656dcfba7b7" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_184fd780-2fca-49a3-8e7e-0bc90dc34763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7ea9fdbc-94bf-4a27-be27-f36fce80f438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b783fd-7ed2-4f67-af6d-1656dcfba7b7" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7ea9fdbc-94bf-4a27-be27-f36fce80f438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_2e1dbc31-bde4-4225-8ed3-5874d2052b52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b783fd-7ed2-4f67-af6d-1656dcfba7b7" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_2e1dbc31-bde4-4225-8ed3-5874d2052b52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e560d115-9c93-46ea-91af-3d3e16091503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b783fd-7ed2-4f67-af6d-1656dcfba7b7" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e560d115-9c93-46ea-91af-3d3e16091503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_b693eee2-41a9-430e-a8a2-e898c4340b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b783fd-7ed2-4f67-af6d-1656dcfba7b7" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_b693eee2-41a9-430e-a8a2-e898c4340b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3c9b4b4c-7e0d-441b-b289-4fe4f19a7426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b783fd-7ed2-4f67-af6d-1656dcfba7b7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3c9b4b4c-7e0d-441b-b289-4fe4f19a7426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad18ad9f-d4d6-4260-9b85-933a15f1d36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fc077a24-a5a1-41c5-8705-0e75e3be46ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad18ad9f-d4d6-4260-9b85-933a15f1d36c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fc077a24-a5a1-41c5-8705-0e75e3be46ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_bb8cd681-dc32-4855-a4f2-4b75e1092914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad18ad9f-d4d6-4260-9b85-933a15f1d36c" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_bb8cd681-dc32-4855-a4f2-4b75e1092914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_de654c0a-0156-4e67-9e20-38c38a9f65c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad18ad9f-d4d6-4260-9b85-933a15f1d36c" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_de654c0a-0156-4e67-9e20-38c38a9f65c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_be02d689-a4d0-4528-a1ba-c325b2f11f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad18ad9f-d4d6-4260-9b85-933a15f1d36c" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_be02d689-a4d0-4528-a1ba-c325b2f11f66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_bbdbdfe0-a03a-4bf6-a899-00ea67b4f066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad18ad9f-d4d6-4260-9b85-933a15f1d36c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_bbdbdfe0-a03a-4bf6-a899-00ea67b4f066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_e8dcfc91-4d75-434d-ab27-e8e42817b0ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad18ad9f-d4d6-4260-9b85-933a15f1d36c" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_e8dcfc91-4d75-434d-ab27-e8e42817b0ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_0e694137-b295-423a-ba8c-34979891f64f" xlink:href="cpix-20200930.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_0e694137-b295-423a-ba8c-34979891f64f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b7e42d21-b7bc-4f0a-93e9-802e34a3f7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b7e42d21-b7bc-4f0a-93e9-802e34a3f7b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d7d32a61-0b40-46a2-b20b-a7f18ecfed59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d7d32a61-0b40-46a2-b20b-a7f18ecfed59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_67c23e56-51b6-44ae-ada4-54ce46d5e6fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_67c23e56-51b6-44ae-ada4-54ce46d5e6fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c58f5568-17cc-42f0-8f9e-788f69f4700f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c58f5568-17cc-42f0-8f9e-788f69f4700f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c73032ab-6a42-42fd-8a45-8444c9e1127a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c73032ab-6a42-42fd-8a45-8444c9e1127a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0f8459cd-c139-4c27-bba6-d2d4b128250b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0f8459cd-c139-4c27-bba6-d2d4b128250b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_3dc5d52f-bbfe-4cb2-bf7a-3e13c8adcaf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_3dc5d52f-bbfe-4cb2-bf7a-3e13c8adcaf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_896756bb-e45a-436f-b2c0-44b0d97871ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_896756bb-e45a-436f-b2c0-44b0d97871ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_9553d423-5b3d-4247-9f5d-6adbec904e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_9553d423-5b3d-4247-9f5d-6adbec904e58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2396ee6b-813c-404f-83bc-bfe3c514cc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_ShareBasedCompensation_2396ee6b-813c-404f-83bc-bfe3c514cc49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7b219fa4-ecce-4be5-aa9a-d22a9889accc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f615672-5485-459b-a669-937c30659f94" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7b219fa4-ecce-4be5-aa9a-d22a9889accc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9f317550-f423-42d8-a46b-62dac3fed472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8313ed24-ad00-42f7-ba88-179cc8609e51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9f317550-f423-42d8-a46b-62dac3fed472" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8313ed24-ad00-42f7-ba88-179cc8609e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_be5ef775-135a-477a-b18a-2caa760af161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9f317550-f423-42d8-a46b-62dac3fed472" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_be5ef775-135a-477a-b18a-2caa760af161" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20200930.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20200930.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20200930.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="cpix-20200930.xsd#InvestmentsinCashEquivalentsandMarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShare"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e6972c98-0040-4aed-b922-f3b4c3c5bc05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f17f781-db36-4bb6-b216-4e5b3bbd9634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e6972c98-0040-4aed-b922-f3b4c3c5bc05" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f17f781-db36-4bb6-b216-4e5b3bbd9634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c671d9c0-fac2-449b-8778-60d633d7055c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e6972c98-0040-4aed-b922-f3b4c3c5bc05" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c671d9c0-fac2-449b-8778-60d633d7055c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20200930.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20200930.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#RevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20200930.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#InventoriesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6044419b-ead2-415a-aac1-eec1e46cd20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_9b3be858-25fe-4f2e-b5f3-e04a3c205f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6044419b-ead2-415a-aac1-eec1e46cd20d" xlink:to="loc_us-gaap_InventoryNoncurrent_9b3be858-25fe-4f2e-b5f3-e04a3c205f0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_a4a35a57-419f-4339-825b-bad8a38e09fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6044419b-ead2-415a-aac1-eec1e46cd20d" xlink:to="loc_us-gaap_InventoryGross_a4a35a57-419f-4339-825b-bad8a38e09fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_df4c44b0-bacc-4d70-8157-fb7cd8b601ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_00c2f830-356a-4079-8d4b-6e7644f7a81b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_df4c44b0-bacc-4d70-8157-fb7cd8b601ed" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_00c2f830-356a-4079-8d4b-6e7644f7a81b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_a801d7c8-4a77-481e-818c-d97c4bbf81fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_df4c44b0-bacc-4d70-8157-fb7cd8b601ed" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_a801d7c8-4a77-481e-818c-d97c4bbf81fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4e109878-e1de-4cef-97ab-6d8b0a8e5900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_df4c44b0-bacc-4d70-8157-fb7cd8b601ed" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4e109878-e1de-4cef-97ab-6d8b0a8e5900" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20200930.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesLeasePositionDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_331e6a50-90d9-4dc5-bf6f-d9a055ddccef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a132fc40-74a2-4849-9b6e-a218a4fa53c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_331e6a50-90d9-4dc5-bf6f-d9a055ddccef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a132fc40-74a2-4849-9b6e-a218a4fa53c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6bf73495-6b2e-4413-b2df-77e622dd0d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_331e6a50-90d9-4dc5-bf6f-d9a055ddccef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6bf73495-6b2e-4413-b2df-77e622dd0d5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_38325fc1-efc8-4e5e-b3c9-9872736282b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_331e6a50-90d9-4dc5-bf6f-d9a055ddccef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_38325fc1-efc8-4e5e-b3c9-9872736282b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_272bf16a-c31a-4939-97af-c034a99cb7e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_331e6a50-90d9-4dc5-bf6f-d9a055ddccef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_272bf16a-c31a-4939-97af-c034a99cb7e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_a7d23506-ab03-495d-a91d-ed7131f83dae" xlink:href="cpix-20200930.xsd#cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_331e6a50-90d9-4dc5-bf6f-d9a055ddccef" xlink:to="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_a7d23506-ab03-495d-a91d-ed7131f83dae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20200930.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7fb7e9d-af8d-432e-89ee-441031ab7c75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3beeec06-5885-4c34-8486-8e00283e57fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7fb7e9d-af8d-432e-89ee-441031ab7c75" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3beeec06-5885-4c34-8486-8e00283e57fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5afcb629-4e96-4d9d-ad8b-7ad22afa1965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7fb7e9d-af8d-432e-89ee-441031ab7c75" xlink:to="loc_us-gaap_OperatingLeaseLiability_5afcb629-4e96-4d9d-ad8b-7ad22afa1965" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20200930.xsd#ShareholdersEquityandDebt"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20200930.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20200930.xsd#IncomeTaxesDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20200930.xsd#CollaborativeAgreements"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRights"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6453ed2e-b58c-407f-bd92-7781527e7e81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_5eca78e2-f972-4f28-a886-d9ffe83b9085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6453ed2e-b58c-407f-bd92-7781527e7e81" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_5eca78e2-f972-4f28-a886-d9ffe83b9085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_781f4c7e-bd27-4260-a2e9-8efa0baa038a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6453ed2e-b58c-407f-bd92-7781527e7e81" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_781f4c7e-bd27-4260-a2e9-8efa0baa038a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_188ac666-d687-443f-89e2-da216f620c29" xlink:href="cpix-20200930.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6453ed2e-b58c-407f-bd92-7781527e7e81" xlink:to="loc_cpix_PaymentsForContingentConsideration_188ac666-d687-443f-89e2-da216f620c29" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_d7623ffa-7f88-4700-b244-f0e70a8596ce" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c6cbfd59-2650-47c2-a9d4-9e8918e0d1fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_d7623ffa-7f88-4700-b244-f0e70a8596ce" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c6cbfd59-2650-47c2-a9d4-9e8918e0d1fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ab7b9271-1f55-4871-b54d-2b3c2647b07f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_d7623ffa-7f88-4700-b244-f0e70a8596ce" xlink:to="loc_us-gaap_Goodwill_ab7b9271-1f55-4871-b54d-2b3c2647b07f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_45e07567-1bf1-4f21-8cb6-e456552a1fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_adb53a37-e8f0-403f-a56a-fce8c7c0c3ae" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_45e07567-1bf1-4f21-8cb6-e456552a1fa3" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_adb53a37-e8f0-403f-a56a-fce8c7c0c3ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_379a8823-66a0-4c23-865e-472922303fad" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_45e07567-1bf1-4f21-8cb6-e456552a1fa3" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_379a8823-66a0-4c23-865e-472922303fad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_62b1a920-8dc3-4dee-a1b0-9254dfd3e1fa" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_45e07567-1bf1-4f21-8cb6-e456552a1fa3" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_62b1a920-8dc3-4dee-a1b0-9254dfd3e1fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_e474c5e2-311f-4c7b-bd4c-872dafe95d03" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_45e07567-1bf1-4f21-8cb6-e456552a1fa3" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_e474c5e2-311f-4c7b-bd4c-872dafe95d03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1cb52246-4a2e-4a50-b1cd-6d43cdb6960c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_cbfe96e8-a3e3-40f8-a875-9af5cd460ce4" xlink:href="cpix-20200930.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1cb52246-4a2e-4a50-b1cd-6d43cdb6960c" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_cbfe96e8-a3e3-40f8-a875-9af5cd460ce4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_a5291336-07f0-4f87-895a-bf76b9956d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_1cb52246-4a2e-4a50-b1cd-6d43cdb6960c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_a5291336-07f0-4f87-895a-bf76b9956d64" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200930.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended"/>
</link:linkbase>
